Journal
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 13, Issue 4, Pages 336-342Publisher
SHENYANG PHARMACEUTICAL UNIV
DOI: 10.1016/j.ajps.2018.01.003
Keywords
Oral disintegrating tablets; Formulation prediction; Artificial neural network; Deep neural network; Deep-learning
Categories
Funding
- University of Macau Research Grant [MYRG2016-00038-ICMS-QRCM, MYRG2016-00040-ICMS-QRCM]
- Macau Science and Technology Development Fund (FDCT) [103/2015/A3]
- National Natural Science Foundation of China [61562011]
Ask authors/readers for more resources
Oral disintegrating tablets (ODTs) are a novel dosage form that can be dissolved on the tongue within 3 min or less especially for geriatric and pediatric patients. Current ODT formulation studies usually rely on the personal experience of pharmaceutical experts and trial-and-error in the laboratory, which is inefficient and time-consuming. The aim of current research was to establish the prediction model of ODT formulations with direct compression process by artificial neural network (ANN) and deep neural network (DNN) techniques. 145 formulation data were extracted from Web of Science. All datasets were divided into three parts: training set (105 data), validation set (20) and testing set (20). ANN and DNN were compared for the prediction of the disintegrating time. The accuracy of the ANN model have reached 85.60%, 80.00% and 75.00% on the training set, validation set and testing set respectively, whereas that of the DNN model were 85.60%, 85.00% and 80.00%, respectively. Compared with the ANN, DNN showed the better prediction for ODT formulations. It is the first time that deep neural network with the improved dataset selection algorithm is applied to formulation prediction on small data. The proposed predictive approach could evaluate the critical parameters about quality control of formulation, and guide research and process development. The implementation of this prediction model could effectively reduce drug product development timeline and material usage, and proactively facilitate the development of a robust drug product. (c) 2018 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available